AbbVie reports 99% cure rate for pan-genotypic Hep C therapy

AbbVie has released late-stage clinical data showing high cure rates for its experimental ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir (G/P) across the majority of patients infected with the virus.

Read on PharmaTimes

NHS to ban sugary drinks in hospitals

Sugary drinks are to be banned in hospital shops from next year unless suppliers voluntarily take decisive action to cut their sales over the next 12 months, NHS England has announced.

Read on PharmaTimes

Aberdeen Uni leads £1.1m study on bleeding plug

A £1.1-million study led by the University of Aberdeen is trialling a new technique that aims to control life-threatening bleeding in trauma victims.

Read on PharmaTimes

FDA rejects Vernalis’ cough cold treatment

The US Food and Drug Administration has rejected Vernalis’ cough cold treatment CCP-07, which is being developed by US partner Tris Pharma.

Read on PharmaTimes

AbbVie’s PARP inhibitor fails in PhIII trials

AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.

Read on PharmaTimes

1 2 3

Top of page

Industry News

AbbVie has released late-stage clinical data showing high cure rates for its experimental ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir (G/P) across...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us